The Effects of HIV Protease Inhibitors in Severe Sepsis
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
Sepsis is the leading cause of death in critically ill patients in the United States. It
develops in approximately 750,000 Americans annually, and more than 210,000 of them die.
Despite improvements in supportive treatment, mortality has changed very little, and until
recently, no sepsis-specific treatments were available. Protease inhibitors have seemed to
have an immune benefit that extends beyond their ability to prevent HIV replication. T cells
in those patients treated with protease inhibitors have reduced rates of death than in those
patients not receiving therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Mayo Clinic
Treatments:
HIV Protease Inhibitors Nelfinavir Protease Inhibitors